The ROLARR randomized clinical trial compared robotic-assisted and conventional laparoscopic surgery for rectal cancer, focusing on an outcome of major practical importance: conversion to open laparotomy. The hypothesis was that robotic technology, with enhanced visualization and instrument dexterity, might make difficult pelvic surgery easier and reduce the need for conversion. Across the trial population, the robotic approach did not demonstrate a statistically significant overall reduction in conversion to open surgery. The result is important because adoption of robotics is often justified by technical advantages that are intuitively appealing but must still translate into clinically meaningful patient outcomes. For surgeons, ROLARR highlights a useful principle: technology should be assessed on the outcomes it changes, not only on what it can do technically. Robotics may still offer advantages in ergonomics, instrument articulation and operating in confined pelvic spaces, and the value may differ according to surgeon experience, anatomy and case complexity. The trial therefore does not make robotic surgery irrelevant; rather, it encourages a more selective and evidence-based approach. For rectal cancer programs, choice of platform should remain connected to oncological quality, surgeon expertise, patient factors, resource availability and the wider multidisciplinary pathway.